HomepageBHC • TSE
add
Bausch Health Companies Inc
Vorige slotkoers
$Â 10,95
Dag-range
$Â 10,74 - $Â 11,11
Jaar-range
$Â 5,45 - $Â 15,43
Beurswaarde
3,90Â mld. CAD
Gem. volume
221,36K
Koers/winst
-
Dividendrendement
-
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 2,51Â mld. | 12,15% |
Bedrijfskosten | 1,27Â mld. | 13,29% |
Netto inkomsten | -85,00Â mln. | 77,51% |
Netto winstmarge | -3,39 | 79,93% |
Winst per aandeel | 1,12 | 9,34% |
EBITDA | 866,00Â mln. | 8,93% |
Effectief belastingtarief | -338,10% | — |
Balans
Totale activa
Totale passiva
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 719,00Â mln. | -5,39% |
Totale activa | 26,54Â mld. | -1,94% |
Totale passiva | 26,78Â mld. | -1,89% |
Totaal aandelenvermogen | -242,00 mln. | — |
Uitstaande aandelen | 367,80 mln. | — |
Koers-boekwaardeverhouding | -3,43 | — |
Rendement op activa | 5,13% | — |
Rendement op kapitaal | 6,37% | — |
Kasstroom
Nettomutatie in liquide middelen
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -85,00Â mln. | 77,51% |
Operationele kasstroom | 405,00Â mln. | 43,62% |
Kasstroom uit beleggingen | -102,00Â mln. | 94,60% |
Kasstroom uit financiering | -189,00Â mln. | -110,41% |
Nettomutatie in liquide middelen | 127,00Â mln. | -33,85% |
Vrije kasstroom | 606,75Â mln. | 261,43% |
Over
Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.
Valeant was originally founded in 1959, as ICN Pharmaceuticals by Milan Panić in California. During the 2010s, Valeant adopted a strategy of buying up other pharmaceutical companies which manufactured effective medications for a variety of medical problems, and then increasing the price of those medications. As a result, the company grew rapidly and in 2015 was the most valuable company in Canada.
Valeant was involved in a number of controversies surrounding drug price hikes and the use of a specialty pharmacy for the distribution of its drugs. This led to an investigation by the U.S. Wikipedia
CEO
Opgericht
1959
Hoofdvestiging
Website
Werknemers
20.270